Patel M, Nieddu G, DeRyke CA, Young K, et al. Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. Antimicrob Agents Chemother 2026;70:e0131325.
PMID: 41586496